While the Khorana Score is a valuable tool, it has certain limitations:
Specificity: It may not accurately predict VTE risk in all cancer types, such as brain tumors or melanoma. Dynamic Factors: The score does not account for dynamic factors like changes in treatment or patient condition. Generalizability: The score was primarily developed and validated in Western populations, which may limit its applicability in other demographic groups.
